Nicox’s lead candidate NCX-470 targets the topical treatment of glaucoma by utilising and expanding on an already-established dual intraocular pressure (IOP)-lowering mechanistic approach. Top-line data from Mont Blanc, the first of two Phase III studies, is expected in H122. The second Phase III trial, Denali, already ongoing in the US, recently received approval to begin enrolling patients in China. Denali study data is expected in Q422, which we believe should support a potential US launch in ....
09 Mar 2021
Nicox - No surprises as NCX-470 Phase III trials advance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Nicox - No surprises as NCX-470 Phase III trials advance
- Published:
09 Mar 2021 -
Author:
Pooya Hemami -
Pages:
6
Nicox’s lead candidate NCX-470 targets the topical treatment of glaucoma by utilising and expanding on an already-established dual intraocular pressure (IOP)-lowering mechanistic approach. Top-line data from Mont Blanc, the first of two Phase III studies, is expected in H122. The second Phase III trial, Denali, already ongoing in the US, recently received approval to begin enrolling patients in China. Denali study data is expected in Q422, which we believe should support a potential US launch in ....